Lilly Arthritis Drug Approved for Alopecia

    June 2022 in “ C&EN global enterprise
    Gina Vitale
    Image of study
    TLDR The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
    Eli Lilly's rheumatoid arthritis drug, Olumiant (baricitinib), has been approved as the first systemic treatment for severe alopecia areata, an autoimmune condition causing hair loss. Olumiant is a daily pill and had also received emergency use authorization from the FDA in May for treating certain hospitalized COVID-19 patients.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 11 results

      community What else is good. Besides the big 3.

      in Chat  34 upvotes 2 months ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community Olumiant active ingredient Baricitinib

      in Research/Science  1 upvotes 2 years ago
      The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

      community I am a dermatologist with a clinical interest in alopecia. AMA

      in Will treatment work for me? 2 years ago
      In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

    Related Research

    4 / 4 results